Adage Capital Partners’s Abivax ABVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$44.6M Sell
400,539
-149,461
-27% -$17.7M 0.07% 275
2025
Q4
$74.2M Sell
550,000
-427,629
-44% -$46.7M 0.11% 176
2025
Q3
$83M Buy
+977,629
New +$59.9M 0.13% 157
2024
Q4
Sell
-530,861
Closed -$6.12M 870
2024
Q3
$6.12M Buy
530,861
+5,861
+1% +$70.2K 0.01% 690
2024
Q2
$6.94M Buy
525,000
+100,000
+24% +$1.43M 0.01% 666
2024
Q1
$6.08M Hold
425,000
0.01% 674
2023
Q4
$4.55M Buy
+425,000
New +$4.33M 0.01% 689

Other funds holding ABVX

Adage Capital Partners's ABVX Position: Q1 2026 in Review

Adage Capital Partners reduced its Abivax (ABVX) stake by 27% in Q1 2026, selling an estimated $17.7M and leaving 400,539 shares worth $44.6M. The position accounts for 0.07% of the portfolio, ranked #275.

Adage Capital Partners first reported a position in ABVX in Q4 2023 and has held it in 7 quarters since. The position peaked at $83M in Q3 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Adage Capital Partners held 400,539 shares of Abivax worth $44.6M as of Q1 2026.
  • Adage Capital Partners sold 149,461 Abivax shares in Q1 2026, an estimated $17.7M.
  • Abivax made up 0.07% of Adage Capital Partners's portfolio in Q1 2026, its #275 holding.
  • Adage Capital Partners first reported a position in Abivax in Q4 2023 and has held it in 7 quarters since.
  • Adage Capital Partners's Abivax position peaked at $83M in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.